Back to Search Start Over

Paroxysmal Nocturnal Hemoglobinuria Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers

Source :
M2 Presswire. November 4, 2024
Publication Year :
2024

Abstract

M2 PRESSWIRE-November 4, 2024-: Paroxysmal Nocturnal Hemoglobinuria Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers (C)1994-2024 M2 COMMUNICATIONS RDATE:01112024 DelveInsight's, 'Paroxysmal Nocturnal Haemoglobinuria Pipeline Insight 2024' report [...]

Subjects

Subjects :
Novartis Pharma AG -- Reports
Regeneron Pharmaceuticals Inc. -- Reports
BioCryst Pharmaceuticals Inc. -- Reports
Reports
Eculizumab -- Reports
Business research -- Reports
Ravulizumab -- Reports
Pharmaceutical industry -- Reports
Business -- Research

Details

Language :
English
Database :
Gale General OneFile
Journal :
M2 Presswire
Publication Type :
News
Accession number :
edsgcl.814662683

Tools

Authors Abstract Subjects Details